BUZZ - Mirum shares rise on positive late-stage clinical trial results for liver disease drug

October 12 - ** Mirum Pharmaceuticals (MIRM.O) shares rose 6.4% premarket to $91.50

** If the gains hold, the opening price will mark a new three-week high

** The pharmaceutical company stated its drug LIVMARLI (maralixibat) met its primary endpoint in a late-stage clinical trial for patients with ultra-rare cholestatic liver disease (link)

** Additional note: Maralixibat significantly reduced pruritus in patients with biliary atresia and lowered serum bile acid levels by 69%

** Biliary atresia: A rare liver condition that, due to blocked bile flow, may cause severe pruritus (itching)

** Plans to submit a supplemental New Drug Application (sNDA) in the U.S. in the first half of 2027 (H127)

** As of the previous trading day’s close, MIRM shares had risen 8.9% year-to-date

(To facilitate non-native English speakers, Reuters automates translation of its reports into several other languages. Because automated translations may be inaccurate or lack needed context, Reuters does not guarantee the accuracy of automated translated texts, which are provided solely for reader convenience. Reuters assumes no liability for any harm or loss resulting from the use of automated translation functions.)